Should pharma Companies avoid Mobile apps? and DigitalHealth

Its easier to say current mobile app model is broken, but at same time they still offer advantages atleast in the first few years when a drug enter the market. But the truth is these apps seldom becomes useful for the larger audience.

Pharma Mobile App Problems

Study among 1814 physicians in 25 specialties shows often pharmaceutical sales reps show medical information that physicians have seen already through other digital and non-digital channels, and most often those digital channels and content are often not even created by pharma companies

Thats because current Pharma Digital projects often run in isolation to a range of existing patient/physician outreach channels, including: e-mail marketing, rep-triggered emails, web-events (webcasts, of conferences and meetings), videos, self-guided e-detailing, remote detailing, product websites, treatment and diagnostic tools (apps), training courses (CME)

Digital to Beyond the Pill

Most pharma companies already uses a central system to manage their websites but nothing of similar nature exists for other digital channels especially the mobile apps. The early concepts of “Digital Factory” where confined to merely outsourcing resources involved in infrastructure and content development to a single IT/BPO vendor. The mobile app Factory need to become essential part of the Digital Pharma 2.0 changes.

Most of the DigitalHealth apps have failed or have seen usage metrics going down after initial hype. Most #digitalhealth apps and #startups fail after initial success because, while we cherish our health we hate being reminded about our sickness.

Read the rest of the Original article at Linkedin 

Advertisements

France to invest €670 million euros for Genomics and Personalized Medicine

Government of France Announce plans to invest €670 million euros or ($760.8 million) for Genomics and Personalized Medicine which will see it establish 12 genome sequencing centers and two national centers for genomic expertise and data analysis. The program would initially focus on cancer, diabetes and rare diseases but after 2020 would expand to include common diseases.

This investment by France follows the release on Wednesday of a report by medical experts examining the possibility of France widening access to genetic medicine within 10 years. A key objective in the report for the first 10 years of the programme is to prepare for the integration of genomic medicine into the normal course of patient care in the country, which means sequencing about 235,000 genomes per year by 2020.

Health Minister Marisol Touraine said Investment in the five year initiative will also come from industry. He also expected Companies like Google, Amazon, Apple and Facebook are interested in the growing genomic medicine sector

Several European countries have already begun to integrate genomic medicine into their health systems and there are large scale genomic initiatives in the UK, US and China. China has even recently announced a Precision Medicine Cloud

 

 

Predictive Analytics for Patient Adherence

The New Medicine Service (NMS) offered by Engalnd’s  NHS community pharmacies came into effect since 1st October 2011. NMS is a patient adherene service and focuses on patients with long term conditions that have been prescribed new medicines.

It is hoped that NMS will lead to the following outcomes:

  • improve medicines adherence
  • increase patient engagement with their condition and medicines, which will support them in making decisions about their treatment and self management
  • reduce medicines wastage
  • reduce hospital admissions due to adverse events associated with medicines
  • increase reporting of medicine adverse reactions by pharmacists and patients
  • positive patient assessments
  • provide evidence base on the effectiveness of the service
  • enable the development of outcome and/or quality measures for community pharmacy

But the Service since launch has seen severe criticism from pharmacists’ over several issues, especially how the pharmacist is re-imbursed for the providing the service which also involved patient counselling.

The answer perhaps can be found by applying predictive analytics to identify patients who are more likely to deviate or other likely to exhibit non-compliance in adhering to the prescription.

Express Scripts has developed a set of proprietary computer models that predict, up to a year in advance, which patients are at risk of not following through on their prescribed drug therapy. details

FICO an analytics service provider also provides medication adherence ranking based on predictive analytics details

AstraZeneca Announce Real-World Evidence Data Collaboration

AstraZeneca Pharmaceuticals LP (NYSE: AZN) and HealthCore, Inc., the health outcomes research subsidiary of WellPoint, Inc. (NYSE: WLP), announced a collaborative agreement to conduct real-world studies designed to determine how to most effectively and economically treat disease

Unlike controlled clinical trials, real-world evidence studies use observational data such as electronic medical records, claims information and patient surveys. By examining data associated with the delivery of care, real-world analyses can assess treatment impact on hospital length of stay, readmissions, overall health status, cost of care and other key evidence-based outcomes.

A leader in health outcomes research, HealthCore maintains the largest data environment in the nation. HealthCore’s near real-time, fully-integrated data environment combines medical, pharmacy, laboratory results and other information drawn from 36 million enrollees in local Blue Cross and/or Blue Shield plans with concentrated populations in 16 states.

 

personalized medicine might be making drug development more complicated

According to a new report from the Tufts Center for the Study of Drug Development at Tufts University 12 to 50 percent of the drugs companies are developing, depending on the company, involved a personalized medicine approach.

The Tufts report is based on a survey of 25 companies, large and small, to which 16 companies responded, as well as interviews with representatives of 13 companies.

Relatively few drugs are now accompanied by such so-called companion diagnostic tests. They are most common in oncology. The breast cancer drug Herceptin, for instance, is given only to women whose tumors have an abundance of a protein called Her2.

According to the report Other key therapeutic areas in which personalized medicine is making headway include cardiovascular, central nervous system, and immunologic therapies, whereas personalized medicine development is just getting started for metabolic and respiratory therapies, as well as virology.

 

Paper instead ‘chips’ may be used as medical testing devices to fight disease

George Whitesides, a Harvard chemistry professor has designed technology in which patients’ blood is dropped on a piece of paper, and water-repellent ink resembling that of a comic book creates diagnostic colors on the other side, CNN reports. The technology may be incorporated into mobile phones, according to CNN.

Whitesides’ prototype allows for testing of STDs and non-sexually transmitted diseases, including HIV, malaria, tuberculosis, hepatitis and gastroenteritis.

 

UK’s Medical Research Council grants Clinical Research consortium $6.4 million to develop chips & software to use mobile phones/PCs as testing devices for sexually transmitted disease (STD)

UK’s Medical Research Council grants a Clinical Research consortium $6.4 million to develop chips & software to use mobile phones/PCs as testing devices for sexually transmitted disease (STD)

If successful individuals will drop their blood, urine or saliva on a mobile chip, which they then insert into a mobile phone or PC. Software on the phone or PC then delivers a diagnosis, schedules a clinic appointment or sends an electronic prescription to a pharmacy. Consumers will be able to purchase the chips in vending machines or at a local pharmacy

%d bloggers like this: